Roche‘s third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus,
the Swiss drugmaker said on Thursday.
Roche third-quarter sales were 13.1 billion Swiss francs ($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll. Sales of Ocrevus were 308 million francs, better than the poll average of 228 million and accelerating from 192 million francs in the second quarter.
Roche third-quarter sales beat forecasts with boost from new multiple sclerosis medicine